Overview

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of the therapy combining GA and NAC on disease activity as reflected by MRI parameters while assessing tolerability and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries
Treatments:
(T,G)-A-L
Acetylcysteine
Glatiramer Acetate
N-monoacetylcystine